<DOC>
	<DOCNO>NCT00076375</DOCNO>
	<brief_summary>Nanocrystalline silver ( small particle silver ) active ingredient Acticoat dressing , approve treatment burn wound . Silver use decade effective antimicrobial agent . In animal study , nanocrystalline silver cream ( NPI ) also demonstrate anti-inflammatory activity . Thus , nanocrystalline silver cream evaluate treatment inflammatory skin condition atopic dermatitis ( eczema ) . Approximately 180 study subject definitive diagnosis mild moderate eczema enrol study . Subjects randomly assign treatment placebo , 0.5 % NPI 1 % NPI 6-week treatment period . Assessments treatment effect safety perform weekly . Upon completion study , subject may eligible 12 week open-label treatment 1 % NPI .</brief_summary>
	<brief_title>Preliminary Study Safety Efficacy Nanocrystalline Silver Cream Atopic Dermatitis ( Eczema )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female , race , 18 65 year age . Females must postmenopausal , surgically sterile , childbearing potential , pregnant ( confirmed test ) use adequate method birth control . Subjects must eczema cover minimum 5 % total body surface area . Subjects must agree use eczema medication 6week study treatment period . Subjects must enrol another investigational drug study . Subjects must allergic silver cocoa butter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Eczema</keyword>
</DOC>